In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Vivo's Deals Of The Month, February 2018

Executive Summary

In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)


Top Alliance: Gilead/Kite Licenses Sangamo's Gene Editing Technology

Gilead Sciences Inc. will pay up to $3.16 billion for exclusive rights to gene editing pioneer  Sangamo Therapeutics Inc.'s zinc finger nuclease technology to help its Kite Pharma Inc. subsidiary create better T cell therapies for cancer. In seeking a partner, Gilead eschewed newer gene editing plays, describing Sangamo's ZFN technology as "the optimal gene editing platform."  The partners have identified some initial oncology targets for specific therapeutic programs and will also attempt to develop CAR-T therapies for solid tumors. [See Deal]

Top Financing: Moderna Raises Another Big, Private Round

mRNA drug developer Moderna Therapeutics LLC added $500 million to its already-full coffers in early February.  New investors Abu Dhabi Investment Authority, BB Biotech, Julius Baer, Singapore-based EDBI and Sequoia Capital China joined existing investors Fidelity Management & Research, Pictet, Viking Global Investors, ArrowMark Partners and Alexandria Venture Investments. Moderna will combine this new money with existing resources to support its 19 development programs, as well as drug discovery for prophylactic vaccines and mRNA therapeutics designed to treat rare diseases. The money also will fund continued investment in the company's technology platform and its manufacturing and digital infrastructure. [See Deal]

Honorable Mention: Cota's $40 Million Series C


COTA Inc., an evidence-based data analytics company, has raised $40 million in Series C financing. IQVIA Holdings led the round and was joined by Memorial Sloan Kettering Cancer Center, EW Healthcare Partners and existing investors Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings. Cota  will use the funding to develop its lead product, the Cota Nodal Address system, which organizes complex real-world data of cancer patients and their diseases in a form that permits detailed analysis of outcomes, toxicities, practice patterns and cost.

 

Top M&A: Roche Acquires RWE With Flatiron Buy

Roche agreed to acquire all outstanding shares of Flatiron Health Inc. for $1.9 billion in cash. The acquisition stems from an existing partnership – Roche previously held a 12.6% equity interest in Flatiron, which operates as a technology platform providing oncology-specific electronic health record software and a suite of software products for advancing real-world evidence of cancer research. The deal is structured so that Flatiron will continue to operate autonomously and it will maintain its network of partnerships. [See Deal]

Advertisement

Related Content

Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
Roche To Improve Real-World Cancer Data Extraction With Flatiron Buy
Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend
Flatiron Aims To Accelerate, Personalize Cancer Research
COTA Inc.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005290

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel